Loading...

The APS have a number of awards recognising excellence

in Pharmaceutical Science

Fellow of the Academy of Pharmaceuticals Sciences

A Fellowship is the highest and most prestigious honour awarded by the APS to members each year in recognition of their contribution to the Academy and their accomplishment and impact in any sector of the Pharmaceutical Sciences. Recipients of the APS Fellowship(s) are recognised at the PharmSci Conference.

A Fellow is an active member of the APS who has provided service to the scientific community, made a significant and distinct contribution to the APS and has had clear impact in pharmaceutical science.

Upon award of a Fellowship, a Fellow will

  • receive recognition from their peers for their excellent achievements in the profession and the field of pharmaceutical science.
  • be able to use the post-nominal letters, FAPS.
  • have opportunities to network with other Fellows, enabling the formation of new collaborations and partnerships.

Following award of a fellowship, the honoured individual is expected to continue to be part of the diverse community of Academy of Pharmaceutical Sciences (APS) fellows who actively contribute to and support the APS, the wider pharmaceutical science community and emerging pharmaceutical scientists.

In addition, a Fellow is expected to:

  • advocate on behalf of the APS and the pharmaceutical science community and by doing so strengthen the voice of the academy and support the future of pharmaceutical science.
  • be inspirational by acting as a role model, and where appropriate a mentor, for the pharmaceutical science community, and in particular the next generation of pharmaceutical scientists, enabling them to develop the experience and expertise they need to become future leaders.

A Fellowship may be awarded following either self-nomination or nomination by a member of the APS. To be eligible for consideration as a Fellow you or your nominator must provide:

  • a one-page statement demonstrating your membership of and contribution to the Academy of Pharmaceutical Scientists and the wider pharmaceutical sciences community, as well as your achievements in pharmaceutical science and their impact over a sustained period (see exemplars).
  • your CV (see specific guidance for CV format below) making sure to include evidence that underpins the information in your one-page document detailing your service to the profession and the achievements you wish to be considered. In line with our commitment to fairness and equality, please make every attempt to remove as much personal, identifiable data as possible from your CV as possible so as to anonymise your application.
  • details of two referees who can assess your contributions/achievements and their impact – ideally at least one of whom is an existing APS Fellow.

There is not a minimum length of APS membership required before a Fellowship can be awarded.  However, it is anticipated that a Fellowship would normally only be awarded to a current member who has made a distinct contribution to APS. If successful in being awarded a Fellowship, you will only retain the award whilst you remain a member of the APS.

Exemplars

A range of exemplars is provided to account for the diversity of the pharmaceutical sciences community. This list is far from inclusive. Although an applicant is likely to be able to demonstrate achievement in more than one of the following areas, no applicant is expected to demonstrate accomplishment in all areas.

Service to the Academy and the Wider Pharmaceutical Science Community

Examples include the effective and sustained:

  • contribution to the training, development or mentoring of pharmaceutical scientists
  • promotion of pharmaceutical science career paths, academic leadership in pharmaceutical science programmes, conference and events leadership
  • contribution to diversity and inclusion and/or widening participation in pharmaceutical science
  • contribution to the public understanding of pharmaceutical science
  • impact through pharmaceutical sciences-based outreach and engagement activities or high-profile promotion of the importance of pharmaceutical science
  • contribution to the enhancement of pharmaceutical sciences, for example supporting the work of the APS.

Achievement in the Pharmaceutical Sciences

Examples include:

  • a substantial contribution to pharmaceutical science education/training, for example by the development of innovative new courses or teaching methods
  • original research, significantly contributing to the advancement of pharmaceutical science or the application of pharmaceutical sciences to significantly advance knowledge in other areas
  • a significant contribution to innovation in pharmaceutical science for example by the publication of patents, with demonstration of their impact
  • creation of a successful business, charity or enterprise, in a pharmaceutical area
  • a significant contribution to the advancement in the quality, safety, efficacy of medicines in any sector of the pharmaceutical sciences
  • significant leadership in the development of an innovative medicine or a diagnostic
  • the development of innovative methods, processes and paths in any of the sectors of pharmaceutical science

Guidance on the format of CVs

The CV is intended to provide evidence in support of the information on the one-page document.

The CV should be no longer than 5 pages (font size 11 is the minimum font that is acceptable and page margins should be at least 2 cm in all directions). Applications exceeding this page limit will not be considered. In line with our commitment to fairness and equality, please make every attempt to remove as much personal, identifiable data as possible from your CV as possible so as to anonymise your application.

A narrative CV has been selected as the best format and a suggested outline can be found below, for further information on narrative CVs please see this link.

  1. Personal details: Use this section to provide personal details such as your education, key qualifications, relevant positions, funding obtained, and awards received.
  2. How have you contributed to the generation and communication of new ideas, hypotheses, tools or knowledge, to innovation in drug development, medicine assessment or manufacturing approaches? This section should capture your contributions to and skills acquired from previous research, innovation or technical projects. It can include a small selection of key outputs such as data sets, software, conference presentations and innovation, medicinal products, research and policy publications.
  3. How have you contributed to research teams and the development of others? Examples might include: project management, supervision, mentoring or line management contributions to the success of a team or advancement of colleagues, involvement in collaborations/networks within your organisation and/or beyond or where you exerted strategic leadership in shaping the direction of a team, organisation, company or institution.
  4. How have you contributed to the wider research and innovation community? Examples might include: commitments including editing, reviewing, refereeing, boards and panels, appointments to positions of responsibility such as committee membership and corporate roles within your department, institution or organisation. Recognition by invitation within your sector, organisation of workshops, conferences or other events that have benefited your research and innovation community and contributions to improving research and innovation culture.
  5. How have you exploited your research or your skills and capabilities as a pharmaceutical scientist? Examples might include: knowledge exchange, engagement with industry, private/public sectors, clients, policy makers, researchers in different fields/disciplines or the broader public and other impacts across research and innovation.
  6. Additional information: This optional section provides an opportunity to include any other relevant additional information relating to your proposal such as career breaks, secondments, volunteering, part-time work and other significant experience (including time spent in different sectors.

Applications to become a Fellow of the Academy of Pharmaceutical Sciences

are now closed for 2024

Please note that applications for APS Fellowships are only open to APS Members

Join APS here

PharmSci Award Lectures

The Academy of Pharmaceutical Sciences is pleased to announce our Call for Nominations for the 2024 APS Award Lecture, to be delivered at APS PharmSci 2024 (4th-6th September 2024) in Huddersfield.

The award will entail the following for the recipient:

• To be presented at APS PharmSci 2024 with complimentary registration for the event on the day

• To deliver a 45 minute lecture within a conference plenary session

• To be recognized as an award recipient on the APS website

Nominations

Nomination should consist of a brief CV and a one page summary of contribution in the following fields:

• Scientific contribution: Work should be outstanding and ambassadorial in their area with an international reputation

• Broad scientific awareness and proposed title of your lecture

Nominations must be made by a member of the Academy.

Selection Process

The recipient of the award will be appointed by a Selection Committee comprising of:
• Representatives of the Academy Board

• Representatives of the APS PharmSci 2024 Organising Committee

Entries should be submitted via email to [email protected]
including ‘PharmSci 2024 Award Lecture’ in the subject field. Your email application must include your full name and postal address, a contact telephone number, your email, and your institution or organisation’s name. The theme of the conference next year is “Beyond Rules of Five: Pharmaceutical Development Over the Next Twenty Years” and we would encourage you to reflect on the actual or potential benefit of your work to patients in your submission.

Entries will be judged by an APS panel.

Closing Date for Entries – 31st January 2024

The Academy of Pharmaceutical Sciences is pleased to announce our Call for Nominations for the Innovative Science Award Lecture 2024, to be delivered at APS PharmSci 2024 (4th-6th September 2024) in Huddersfield.

Entrants are welcome from researchers in pharmaceutical science from across the globe in academia, industry, public service or other scientific establishments. The individual applicant should have demonstrated, through published work, a significant innovation which has the potential for application within the pharmaceutical industry.

Submission Criteria

Applicants are requested to submit their CV and a synopsis of their research of not more than 500 words, focussing on its importance to the pharmaceutical industry and proposed title of your lecture.

Entries should be submitted via email to [email protected] including ‘Innovative Science Award 2024’ in the subject field. Your email application must include your full name and postal address, a contact telephone number, your email, and your institution or organisation’s name. The theme of the conference next year is “Beyond Rules of Five: Pharmaceutical Development Over the Next Twenty Years” and we would encourage you to reflect on the actual or potential benefit of your work to patients in your submission.

Entries will be judged by an APS panel.

Prize

The winner will receive an invitation to present the Innovative Science Award Lecture on their work at APS PharmSci 2024, at the University of Huddersfield from 4th-6th September 2024.

Closing Date for Entries – 31st January 2024

The Academy of Pharmaceutical Sciences is pleased to announce our Call for Nominations for the 2024 Emerging Scientist Award Lecture, to be delivered at APS PharmSci 2024 (4th-6th September 2024) in Huddersfield.

Entrants are welcome from researchers from across the globe in academia, industry, public service or other scientific establishments. Applicants should be no more than 10 years since award of their degree or PhD, and have an outstanding track record (for this stage of their career) indicative of excellent potential.

Submission Criteria

Both nominations and self-nominations are welcome.

Submission should include:

• A one-page cover letter, highlighting key achievements of the candidate in the field of pharmaceutical science and suitability for the award. The theme of the conference next year is “Beyond Rules of Five: Pharmaceutical Development Over the Next Twenty Years” and we would encourage you to reflect on the actual or potential benefit of your work to patients in your submission.
• A detailed CV
• Proposed title of your talk

Prize

The winner will receive an invitation to present the Emerging Scientist Award Lecture on their work at PharmSci 2024, at the University of Huddersfield from 4th-6th September 2024.

Entries should be submitted via email to [email protected] including ‘Emerging Scientist Award 2024’ in the subject field. Your email application must include your full name and postal address, a contact telephone number, your email, and your institution or organisation’s name.

Entries will be judged by an APS panel.

Closing Date for Entries – 31st January 2024

Previous Winners

David Jones is internationally recognised for his research concerning the application of biomaterials science/engineering to address the industrial and clinical issues associated with implants and pharmaceutical dosage forms, including:

· Polymer platforms/coatings to inhibit life-threatening problems associated with medical devices
· Implants that adhere to tissues upon application and offer engineered drug-elution rates. Commercialisation includes treatments for infection in farmed animals (Provita-Eurotech) and the development of novel stoma sealants (TG Eakin).
· Use of polymer extrusion technologies to improve drug release and to provide targeted and multiple drug delivery options. This research has influenced manufacture practice and dosage form design.
· Biodegradable ocular implants providing controlled drug delivery, designed to treat sight-threatening diseases. This technology has resulted in the establishment of a spin-out company (Re-
Vana, of which Jones is a founder/Chief Scientist).

Jones is an internationally recognised scholar who has uniquely been elected to three National Academies, namely the Royal Academy of Engineering, the Academy of Medical Sciences, and the Royal Irish Academy (the National Academy of Ireland). He has also been elected to Fellowships of the Irish Academy of Engineering, the Institute of Materials, Minerals and Mining, the Royal Society of Chemistry, Royal Statistical Society, the Pharmaceutical Society of Northern Ireland and to an Eminent Fellowship of the Academy of Pharmaceutical Sciences.

He has received four international research awards, namely the British Pharmaceutical Conference Science Medal Award, the Lilly Prize for Pharmaceutical Excellence, the Academy of Pharmaceutical Sciences Innovation Award and the Griffith Medal of Institute of Materials, Minerals and Mining.

His research has enhanced the sales of companies (>£20M), has increased employment (32
staff) and has allowed companies to expand their businesses.

Jones has an exceptional publication record, as evidenced by his H-index and Citations
Jones’ research has received >£15M funding and he has supervised 17 KTP/Fusion programmes, resulting in 21 commercialised products. Noteworthy is the award-winning viscoelastic device (Cohesive Paste™), designed/developed to improve stoma health and patients’ quality of life.

His proposed title for the Award lecture is, “Acrylates, Hydrogels and Flashing Lights: designing clinically relevant implants and drug delivery systems.’

Martin has over 20 years’ experience working in the pharmaceutical industry and is currently a Royal Society Entrepreneur in Residence fostering closer collaboration between industry and academia. Martin was Chief Executive Officer of Diurnal Group plc and led the company for nearly 15 years, raising over £100m in investment, including the floatation of Diurnal on the London Stock Exchange (AIM) in 2015 in a £75m initial public offering. Martin was an inventor of the company’s lead products: Alkindi® and Efmody® which have now been approved worldwide for the treatment of rare diseases of cortisol deficiency. Martin was responsible for the subsequent commercialisation of these products before the eventual sale of Diurnal to Neurocrine Biosciences in 2022.

Martin is also Director of D3 Pharma Limited which has successfully commercialised Plenachol®, a high dose Vitamin D product prescribed in the UK. Previously, Martin worked for Fusion IP plc with responsibility for commercialising research from the Faculty of Medicine, Dentistry and Health at the University of Sheffield. Prior to this, Martin was Operations Director of Critical Pharmaceuticals Limited, a venture capital-backed drug delivery company spun out of the University of Nottingham developing long-acting growth hormone products.
Martin is a scientist by background with a PhD in Pharmaceutical Science from the University of Nottingham and a BSc (Hons) in Biochemistry from the University of Bristol. Martin spent a year working for Pfizer (Sandwich, UK). Martin is also currently an Endocrine Entrepreneur in Residence at The University of Sheffield.

Zahra Rattray is a Senior Lecturer in Translational Pharmaceutics at the University of Strathclyde Institute of Pharmacy and Biomedical Sciences. She is a registered pharmacist, obtaining her MPharm (2008) and PhD in drug delivery (2013) from the University of Manchester School of Pharmacy and Pharmaceutical Sciences. Zahra was a senior scientist at AstraZeneca (2014-2016) contributing to the early development and parenterals development portfolio, and later completed postdoctoral training at the Yale School of Medicine (2016-2018). She is lead for the Academy of Pharmaceutical Sciences Advanced Therapy Medicinal Products and Biotherapeutics focus group, a Fellow of the Higher Education Academy and a member of the Royal Society of Edinburgh Young Academy of Scotland. She was included in the International Federation of Pharmacy Woman in Science and Education 2022 inaugural (FIPWISE) rising star list. Zahra is director for Pharmacy public engagement and outreach, and an advocate for making pharmaceutical sciences equitable and accessible to all.

In her career to-date, Zahra has been inventor on four granted patents, published one book chapter and >20 peer-reviewed publications. Zahra’s interdisciplinary team research physicochemical determinants of drug delivery system biological function and how altered biochemistry in cancer underpins resistance to standard of care chemotherapies. Her research goal in the long term is to develop bioinspired drug delivery systems targeting tumour biochemical vulnerabilities for unmet clinical need.